Durand, L., Keenan, E., Boland, F., Harnedy, N., Delargy, Í., Scully, M., Mayock, P., Ebbitt, W., Vázquez, M. O., Corrigan, N., Killeen, N., Pate, M., Byrne, P., & Cousins, G. (2022). Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study. International Journal of Drug Policy, Prépublication, 103768. https://doi.org/10.1016/j.drugpo.2022.103768
Glegg, S., McCrae, K., Kolla, G., Touesnard, N., Turnbull, J., Brothers, T. D., Brar, R., Sutherland, C., Le Foll, B., Sereda, A., Goyer, M.-È., Rai, N., Bernstein, S., & Fairbairn, N. (2022). “COVID just kind of opened a can of whoop-ass”: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. International Journal of Drug Policy, 106, 103742. https://doi.org/10.1016/j.drugpo.2022.103742
Jalodia, R., Antoine, D., Braniff, R. G., Dutta, R. K., Ramakrishnan, S., & Roy, S. (2022). Opioid-Use, COVID-19 Infection, and Their Neurological Implications. Frontiers in Neurology, 13, 884216. https://doi.org/10.3389/fneur.2022.884216
Vallecillo, G., Durán, X., Canosa, I., Roquer, A., Martinez, M. C., & Perelló, R. (2022). COVID-19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain. Drug and Alcohol Review, Prépublication. https://doi.org/10.1111/dar.13502
Owiti, J. A., Benson, M., Maplanka, M., Oluseye, L., & Carvalho, D. (2022). Is Methadone Safe for Patients With Opioid Use Disorder and Coronavirus Disease 2019 Infection? Journal of Addictions Nursing, 33(2), 86–94. https://doi.org/10.1097/JAN.0000000000000457
Iversen, J., Wand, H., Kemp, R., Bevan, J., Briggs, M., Patten, K., Heard, S., & Maher, L. (2022). Uptake of COVID-19 vaccination among people who inject drugs. Harm Reduction Journal, 19(1), 59. https://doi.org/10.1186/s12954-022-00643-3
Banks, D. E., Paschke, M. E., Li, X., Fentem, A., Rich, A., Szlyk, H. S., & Cavazos-Rehg, P. (2022). Opioid Use Disorder and COVID-19: Treatment and Recovery Factors among Vulnerable Populations at the Intersection of Two U.S. Epidemics. Journal of Psychoactive Drugs, 0(0), 1–9. https://doi.org/10.1080/02791072.2022.2079443
May, T., Dawes, J., Fancourt, D., & Burton, A. (2022). A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives. International Journal of Drug Policy, 106, 103752. https://doi.org/10.1016/j.drugpo.2022.103752
Lei, F., Lofwall, M. R., Freeman, P. R., Slade, E., Vickers-Smith, R., & Slavova, S. (2022). Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky. The Journal of Rural Health, Prépublication. https://doi.org/10.1111/jrh.12669
Hoffman, K. A., Foot, C., Levander, X. A., Cook, R., Terashima, J. P., McIlveen, J. W., Korthuis, P. T., & McCarty, D. (2022). Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Journal of Substance Abuse Treatment, Prépublication, 108801. https://doi.org/10.1016/j.jsat.2022.108801
Alinsky, R. H., Prichett, L., Chang, H.-Y., Alexander, G. C., Stein, B. D., & Saloner, B. (2022). Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic. Journal of Adolescent Health. https://doi.org/10.1016/j.jadohealth.2022.03.015
Chen, C., & Shen, S. (2022). Trend analysis of drug overdose deaths before and during the COVID-19 pandemic. American Journal of Translational Research, 14(4), 2685–2688. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091116/
Williams, L. D., Lee, E., Latkin, C., Mackesy-Amiti, M. E., Kaufmann, M., Copulsky, E., Kaplan, C., & Boodram, B. (2022). Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs. International Journal of Environmental Research and Public Health, 19(9), 5351. https://doi.org/10.3390/ijerph19095351
Hoffman, K. A., Foot, C., Levander, X. A., Cook, R., Terashima, J. P., McIlveen, J. W., Korthuis, P. T., & McCarty, D. (2022). Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Journal of Substance Abuse Treatment, Prépublication, 108801. https://doi.org/10.1016/j.jsat.2022.108801
Walters, S. M., Perlman, D. C., Guarino, H., Mateu-Gelabert, P., & Frank, D. (2022). Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities. Substance Use & Misuse, Prépublication. https://doi.org/10.1080/10826084.2022.2064509
Garcia, G.-G. P., Stringfellow, E. J., DiGennaro, C., Poellinger, N., Wood, J., Wakeman, S., & Jalali, M. S. (2022). Opioid overdose decedent characteristics during COVID-19. Annals of Medicine, 54(1), 1081–1088. https://doi.org/10.1080/07853890.2022.2067350
Swann, W. L., Schreiber, T. L., Kim, S. Y., McNeely, H., & Hong, J. H. (2022). Perceived impact of COVID-19 on prevention, treatment, harm reduction, and recovery services for opioid use disorder: National survey of local health departments. Substance Abuse, 43(1), 993–998. https://doi.org/10.1080/08897077.2022.2060429
Hughes, T. M., Kalicki, A., Huxley-Reicher, Z., Toribio, W., Samuels, D. L., Weiss, J. J., Herscher, M., & Wang, L. (2022). A medical student-led model for telephone-based opioid overdose education and naloxone distribution during the COVID-19 pandemic. Substance Abuse, 43(1), 988–992. https://doi.org/10.1080/08897077.2022.2060426
Bouck, Z., Scheim, A. I., Gomes, T., Ling, V., Caudarella, A., & Werb, D. (2022). Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. International Journal of Drug Policy, 104, 103680. https://doi.org/10.1016/j.drugpo.2022.103680
Garg, R., Kitchen, S. A., Men, S., Campbell, T. J., Bozinoff, N., Tadrous, M., Antoniou, T., Wyman, J., Werb, D., Munro, C., & Gomes, T. (2022). Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis. Drug and Alcohol Dependence, 236, 109459. https://doi.org/10.1016/j.drugalcdep.2022.109459
Potaka, K. L., Freeman, R., Soo, D., Nguyen, N.-A., Sim, T. F., & Moullin, J. C. (2022). Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19. BMC Emergency Medicine, 22(1), 62. https://doi.org/10.1186/s12873-022-00604-w
Bandara, S., Maniates, H., Hulsey, E., Smith, J. S., DiDomenico, E., Stuart, E. A., Saloner, B., & Krawczyk, N. (2022). Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. BMC Health Services Research, 22(1), 418. https://doi.org/10.1186/s12913-022-07832-7
Kiang, M. V., Acosta, R. J., Chen, Y.-H., Matthay, E. C., Tsai, A. C., Basu, S., Glymour, M. M., Bibbins-Domingo, K., Humphreys, K., & Arthur, K. N. (2022). Sociodemographic and geographic disparities in excess fatal drug overdoses during the COVID-19 pandemic in California: A population-based study. The Lancet Regional Health - Americas, 11, 100237. https://doi.org/10.1016/j.lana.2022.100237
Lew, B., Bodkin, C., Lennox, R., O’Shea, T., Wiwcharuk, G., & Turner, S. (2022). The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduction Journal, 19(1), 29. https://doi.org/10.1186/s12954-022-00614-8
Mun, C. J., Campbell, C. M., McGill, L. S., Wegener, S. T., & Aaron, R. V. (2022). Trajectories and individual differences in pain, emotional distress, and prescription opioid misuse during the COVID-19 pandemic: A one-year longitudinal study. The Journal of Pain. https://doi.org/10.1016/j.jpain.2022.02.005
Burgess-Hull, A. J., Smith, K. E., Panlilio, L. V., Schriefer, D., Preston, K. L., Alter, A., Yeager, C., Chizmar, T., Delbridge, T., Zamore, K., Beeson, J., & Epstein, D. H. (2022). Nonfatal opioid overdoses before and after Covid-19: Regional variation in rates of change. PLOS ONE, 17(3), e0263893. https://doi.org/10.1371/journal.pone.0263893
McNeil, R., Fleming, T., Mayer, S., Barker, A., Mansoor, M., Betsos, A., Austin, T., Parusel, S., Ivsins, A., & Boyd, J. (2022). Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021. American Journal of Public Health, e1–e8. https://doi.org/10.2105/AJPH.2021.306692
Hodges, J., Waselewski, M., Harrington, W., Franklin, T., Schorling, K., Huynh, J., Tabackman, A., Otero, K., Ingersoll, K., Tiouririne, N. A.-D., Flickinger, T., & Dillingham, R. (2022). Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown. Addiction Science & Clinical Practice, 17(1), 16. https://doi.org/10.1186/s13722-022-00296-4
Sarker, A., Nataraj, N., Siu, W., Li, S., Jones, C. M., & Sumner, S. A. (2022). Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts. Substance Abuse Treatment, Prevention, and Policy, 17(1), 16. https://doi.org/10.1186/s13011-022-00442-w
Page, T. F., Chen, W., Jacko, J. A., & Sainfort, F. (2022). Disparities in Emergency Department Visits for Opioid and Stimulant Overdoses in Florida During COVID-19. Population Health Management, Prépublication. https://doi.org/10.1089/pop.2021.0369
Samuel, L., Caygill-Walsh, R., Suen, L. W., Mohebbi, S., & Geier, M. (2022). Triple Threat: Response to the Crises of COVID-19, Homelessness, and Opioid Use Disorder With a Novel Approach to Buprenorphine Delivery: A Case Series. Journal of Addiction Medicine, Prépublication. https://doi.org/10.1097/ADM.0000000000000989
Kitchen, S. A., Campbell, T. J., Men, S., Bozinoff, N., Tadrous, M., Antoniou, T., Wyman, J., Werb, D., Munro, C., & Gomes, T. (2022). Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis. International Journal of Drug Policy, 103644. https://doi.org/10.1016/j.drugpo.2022.103644
McRae, M., Sardiwalla, Y., Nachmani, O., Price, E., Huynh, M., & Coroneos, C. (2022). Upper Extremity Infection Related to Intravenous Drug Use: Considering the True Cost of the COVID-19 Pandemic and Lockdown. HAND, 15589447221077376. https://doi.org/10.1177/15589447221077377
Ghose, R., Forati, A. M., & Mantsch, J. R. (2022). Impact of the COVID-19 Pandemic on Opioid Overdose Deaths: a Spatiotemporal Analysis. Journal of Urban Health, Prépublication. https://doi.org/10.1007/s11524-022-00610-0
Martin, C. E., Thakkar, B., Taylor, D. D. H., & Chapman, D. A. (2022). Disparities by Sex in COVID-19 Risk and Related Harms Among People with Opioid Use Disorder. Journal of Women’s Health, Prépublication. https://doi.org/10.1089/jwh.2021.0457
Liu, M., Richard, L., Campitelli, M. A., Nisenbaum, R., Dosani, N., Dhalla, I. A., Wadhera, R. K., Shariff, S. Z., & Hwang, S. W. (2022). Drug Overdoses During the COVID-19 Pandemic Among Recently Homeless Individuals. Addiction, Prépublication. https://doi.org/10.1111/add.15823
Dee L MacMillan, K., Morrison, T. M., Melvin, P., Diop, H., Gupta, M., & Wachman, E. M. (2022). Impact of Coronavirus Disease-2019 on Hospital Care for Neonatal Opioid Withdrawal Syndrome. The Journal of Pediatrics, Prépublication. https://doi.org/10.1016/j.jpeds.2022.02.001
Friedman, J., & Gjersing, L. (2022). Increases in drug overdose deaths in Norway and the United States during the COVID-19 pandemic. Scandinavian Journal of Public Health, Prépublication, 14034948221075024. https://doi.org/10.1177/14034948221075025
Auty, S. G., & Griffith, K. N. (2022). Medicaid Expansion and Drug Overdose Mortality during the COVID-19 Pandemic in the United States. Drug and Alcohol Dependence, Prépublication, 109340. https://doi.org/10.1016/j.drugalcdep.2022.109340
Trayner, K. M. A., McAuley, A., Palmateer, N. E., Yeung, A., Goldberg, D. J., Glancy, M., Hunter, C., Ritchie, T., Craik, J., Raeburn, F., McTaggart, S., Barnsdale, L., Campbell, J., Shepherd, S. J., Bradley-Stewart, A., Gunson, R. N., Templeton, K., & Hutchinson, S. J. (2022). Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study. Drug and Alcohol Dependence, Prépublication, 109263. https://doi.org/10.1016/j.drugalcdep.2021.109263
Cheng, A., Badolato, R., Segoshi, A., McDonald, R., Malone, M., Vasudevan, K., Badiei, B., Sugarman, A., Macdonald, R., Mangat, J., Giftos, J., Lee, J. D., & Tofighi, B. (2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addiction Science & Clinical Practice, 17(1), 4. https://doi.org/10.1186/s13722-022-00288-4
Sprague, J. E., Yeh, A. B., Lan, Q., Vieson, J., & McCorkle, M. (2022). COVID-19 economic impact payments and opioid overdose deaths. International Journal of Drug Policy, 102, 103608. https://doi.org/10.1016/j.drugpo.2022.103608
Mistler, C. B., Sullivan, M., Wickersham, J. A., Copenhaver, M. M., & Shrestha, R. (2022). Clinical and demographic differences in the willingness to use self-administered at-home COVID-19 testing measures among persons with opioid use disorder. Substance Abuse, 43(1), 708–712. https://doi.org/10.1080/08897077.2021.2007511
Iacono, T. M. (2022). Modernizing regulations for treating opioid use disorder during the COVID-19 pandemic. Journal of the American Academy of PAs, 35(2), 57–59. https://doi.org/10.1097/01.JAA.0000805844.19200.b3
Behrends, C. N., Lu, X., Corry, G. J., LaKosky, P., Prohaska, S. M., Glick, S. N., Kapadia, S. N., Perlman, D. C., Schackman, B. R., & Des Jarlais, D. C. (2022). Harm Reduction and Health Services provided by Syringe Services Programs in 2019 and subsequent impact of COVID-19 on Services in 2020. Drug and Alcohol Dependence, Prépublication, 109323. https://doi.org/10.1016/j.drugalcdep.2022.109323
Jessell, L., Zaidi, I., Dominguez-Gomez, L., & Harocopos, A. (2022). Collecting Data During the COVID-19 Pandemic: Lessons From an In-Person Survey of People Who Use Opioids. Public Health Reports, Prépublication, 00333549211063473. https://doi.org/10.1177/00333549211063473
Zapata, J., Lesser, J., Recto, P., Moreno-Vasquez, A., & Idar, A. Z. (2022). Perceptions of Community Health Workers during Two Concurrent National Health Crises: Opioid Use Disorder and COVID-19. Issues in Mental Health Nursing, Prépublication. https://doi.org/10.1080/01612840.2021.2011508
Dadiomov, D., Trotzky-Sirr, R., Shooshtari, A., & Qato, D. M. (2022). Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic. Drug and Alcohol Dependence, 232, 109291. https://doi.org/10.1016/j.drugalcdep.2022.109291
Sung, M. L., Black, A. C., Blevins, D., Henry, B. F., Cates-Wessel, K., Dawes, M. A., Drexler, K., Hagle, H., Molfenter, T., Levin, F. R., Becker, W. C., & Edelman, E. J. (2022). Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. Journal of Addiction Medicine, Prépublication. https://doi.org/10.1097/ADM.0000000000000948
Bishop, L. D., & Rosenberg-Yunger, Z. R. S. (2022). Pharmacists expanded role in providing care for opioid use disorder during COVID-19: A qualitative study exploring pharmacists’ experiences. Drug and Alcohol Dependence, 232, 109303. https://doi.org/10.1016/j.drugalcdep.2022.109303